Valneva gains after new Phase 3 data for chikungunya vaccine in adolescents

Valneva (NASDAQ:VALN) ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for people aged 12–17 years old in Brazil.

According to the company, new